Skip to content


  • Poster presentation
  • Open Access

Rapidly progressive glomerulonephritis, thrombotic microangiopathy and amebic colitis: a challenging case report

  • 1,
  • 2,
  • 1,
  • 3,
  • 2,
  • 4,
  • 4,
  • 5 and
  • 6
Pediatric Rheumatology201412 (Suppl 1) :P291

  • Published:


  • Hemolytic Uremic Syndrome
  • Eculizumab
  • Thrombotic Microangiopathy
  • Crescentic Glomerulonephritis
  • ADAMTS13 Activity


Thrombotic microangiopathy (TMA) describes a pathological process of microvascular thrombosis, consumptive thrombocytopenia and microangiopathic haemolytic anaemia, leading to end-organ ischaemia and infarction. TMA is a feature of a number of clinical disorders, most commonly hemolytic uremic syndrome (HUS) and thrombotic thrombocytopaenic purpura. Several molecular mechanisms mediating TMA have been elucidated; however, challenges remain in distinguishing specific causes of TMA in the presence of overlapping clinical features.


We aim to report a case of thrombotic microangiopathy, rapidly progressive glomerulonephritis and amebic colitis.


A 12 year old previously healthy boy was admitted with acute renal injury, requiring dialysis. Initial lab exams revealed urea of 213 mg/dL, creatinine 6.0 mg/dL, hematocrit 18%, hemoglobin 7 g/dL, thrombocytopenia, LDH 5900 mg/dL, urine protein-to-creatinine ratio of 4.3, and low C3. Due to evolution with myocardial dysfunction and pericardial tamponade, IV methylprednisolone (MP) pulses were started and he developed massive gastrointestinal bleeding due to amebic colitis, evidenced at colonic biopsy. Plasmapheresis, gammaglobulin, metronidazole and teclosan, were initiated, and after infection control: MP pulses, Rituximab, cyclophosphamide and therapeutic low-molecular weight heparin. Renal biopsy revealed crescentic glomerulonephritis, IgG and C3 on glomeruli, and C1q tubular deposits, but also arteriolar TMA. Despite this, he developed end stage renal disease. Serial autoantibodies tests were negative. ADAMTS13 activity assay was 80%. Immunological investigation performed after immunosuppression showed persistent and marked reduction of serum IgA/IgM/IgG and lymphocyte, even after discontinuation of cyclophosphamide and rituximab. This patient currently has mild thrombocytopenia, leukopenia, lymphopenia, laboratorial signs of hemolysis, and livedo reticularis. Genetic studies for complement-mediated diseases are pending.


This is a case with severe evolution, characterized by rapidly progressive glomerulonephritis and TMA. The main question is whether this patient has atypical HUS, perhaps associated with amebic dysentery, or an antiphospholipid syndrome. The persistently negative autoantibodies, and the partial response to the adopted treatment, made pSLE less probable.


The persistent active disease and the extreme difficulty of vascular access for renal replacement therapy make it urgent to perform kidney transplantation. Considering the high risk of disease relapse and subsequent loss of renal graft, it is essential to confirm the diagnosis to decide to use eculizumab (anti-C5 monoclonal antibody) or not, and especially to ensure better post-transplant prognosis.

Disclosure of interest

None declared.

Authors’ Affiliations

Pediatric Rheumatology, Hospital Federal dos Servidores do Estado, Rio de Janeiro, Brazil
Pediatric Nephrology, Hospital Federal dos Servidores do Estado, Rio de Janeiro, Brazil
Hospital Federal dos Servidores do Estado, Rio de Janeiro, Brazil
Pediatric Immunology, Hospital Federal dos Servidores do Estado, Rio de Janeiro, Brazil
Pathology, Bioneo Lab, Rio de Janeiro, Brazil
Pediatric Rheumatology, IPPMG-UFRJ, Rio de Janeiro, Brazil


© Fonseca et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.